EUVIMEDEUVIMED entdecken
Open Access

Metabolic effects of testosterone therapy in transgender and gender diverse individuals with polycystic ovary syndrome

Justine Herndon iD, John Anderson McNeil, Salym Winter, Alice Y Chang iD

The Journal of Clinical Endocrinology & Metabolism · 2026

DOI: 10.1210/clinem/dgag032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Justine Herndon und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, Mayo Clinic, Rochester, MN 55905, USA. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Testosterone, Transgender Persons, Cardiovascular Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Center for Advancing Translational Sciences (NCATS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Polycystic ovary syndrome (PCOS) affects 10% to 13% of individuals assigned female at birth (AFAB), although a greater prevalence is reported in transgender/gender diverse individuals (TGD) (23.8-38.8%). Testosterone therapy (TT) in TGD individuals is linked to worsening cardiovascular risk factors (CVRFs). Whether TT induces more adverse cardiometabolic changes in TGD with PCOS than TGD without PCOS remains uncertain.

Objective

To compare the effects of TT on CVRF in TGD with and without PCOS.

Methods

We retrospectively reviewed 373 records to identify 62 TGD with PCOS (withestablished guideline criteria) and 132 age-matched TGD without PCOS. Data included longitudinal anthropometric measurements, hormone and metabolic parameters, and CVRF before and after TT. Group comparison of PCOS vs without PCOS before and after TT was conducted via independent t-tests, Mann–Whitney-U, and Chi-square.

Results

At baseline, TGD with PCOS had significantly greater body mass index (BMI), obesity prevalence, and, after controlling for BMI, baseline metformin use. There were no significant differences between TGD with and without PCOS when comparing intra-participant changes after TT. Controlling for BMI, TGD with PCOS on TT exhibited significantly greater hyperlipidemia prevalence, alanine transaminase (ALT) levels, and bioavailable testosterone concentrations than TGD without PCOS on TT.

Conclusion

Greater baseline cardiometabolic risk was largely BMI-related in TGD with PCOS compared to TGD without PCOS. Only hyperlipidemia and elevated ALT were more prevalent during TT after adjusting for BMI. These findings support cardiometabolic monitoring during TT in all TGD individuals without significant increased risk with PCOS history.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycystic Ovary SyndromeTestosteroneTransgender PersonsCardiovascular DiseasesHumansFemaleRetrospective StudiesAdultMaleBody Mass IndexGender-Nonconforming PersonsYoung AdultObesityAndrogens

Stichwörter der Autor:innen

androgen excesscardiovascular riskgender-affirming hormone therapytransmasculine

Substanzen

TestosteroneAndrogens

Autor:innen und Institutionen

  • Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, Mayo Clinic, Rochester, MN 55905, USA.
  • Division of Endocrinology, Diabetes, and Nutrition, Mayo Clinic, Jacksonville, FL 32224, USA.

ORCID-Profile: Justine Herndon, Alice Y Chang

Förderung

  • National Center for Advancing Translational Sciences (NCATS)

Zitieren

APA

Herndon, J., McNeil, J. A., Winter, S., & Chang, A. Y. (2026). Metabolic effects of testosterone therapy in transgender and gender diverse individuals with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag032

Vancouver

Herndon J, McNeil JA, Winter S, Chang AY. Metabolic effects of testosterone therapy in transgender and gender diverse individuals with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag032

BibTeX
@article{Herndon2026,
  author = {Herndon, Justine and McNeil, John Anderson and Winter, Salym and Chang, Alice Y},
  title = {Metabolic effects of testosterone therapy in transgender and gender diverse individuals with polycystic ovary syndrome},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgag032}
}
Kostenlos starten →